Invivo Capital Partners
VC Fund
Barcelona, Spain
Invivo Capital Partners is a VC fund in Barcelona focused on Biotechnology and Pharmaceutical. Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $44M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Invivo Capital Partners invests in
Stages Invivo Capital Partners invests in
Countries Invivo Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.6M–$13M
- Series A
- $2.2M–$70M
- Venture - Series Unknown
- $3.3M–$8.9M
Investment Focus
Industry
- Biotechnology 8 (23%)
- Pharmaceutical 4 (11%)
- Health Care 2 (6%)
- Life Science 2 (6%)
- Therapeutics 2 (6%)
Stage
- Seed 9 (26%)
- Series A 4 (11%)
- Venture - Series Unknown 3 (9%)
- Funding Round 2 (6%)
- Series B 1 (3%)
Country
- Spain 7 (20%)
- France 3 (9%)
- Belgium 1 (3%)
- Denmark 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Albert Ferrer
Founding Partner
|
Founding Partner | Total investments: 12 | Find email | |
Lluis Pareras
Partner
|
Partner | Total investments: 14 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Telum Therapeutics
|
Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M / Series A / Jul 01, 2026 | |
| Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | $13M / Seed / May 06, 2026 | ||
| ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | ||
| Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M / Seed / Sep 08, 2025 | ||
| Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | Seed / Mar 18, 2025 | ||
| Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions. | $20.6M / Series A / Jan 08, 2025 | ||
Gyala Therapeutics
|
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytesare obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas. | $3.3M / Venture - Series Unknown / Oct 14, 2024 | |
| EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $2.2M / Series A / Dec 12, 2023 | ||
| Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $69.5M / Series A / Sep 07, 2023 | ||
| OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez. | $7.3M / Seed / Jun 22, 2023 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Invivo Capital Partners invest in?
Invivo Capital Partners invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Seed and Series A stage. Most of the 35 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Invivo Capital Partners invest in?
Invivo Capital Partners typically joins rounds of $1.6M–$13M at Seed, $2.2M–$70M at Series A and $3.3M–$8.9M at Venture - Series Unknown. These are whole funding-round sizes, not Invivo Capital Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Invivo Capital Partners took part in.
How do I contact Invivo Capital Partners?
Public channels for Invivo Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Invivo Capital Partners?
The team at Invivo Capital Partners includes Albert Ferrer (Founding Partner) and Lluis Pareras (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
